There are currently many ocular disorders that are characterised by limitations in the repair of affected tissues and which present themselves as unresolved pathologies or post-operative complications. At BTI, we're searching for a solution to these problems through different research projects. Likewise, over the last decade, our research team has been working on the development of autologous eye drops for the ocular surface that have a standardised, predictable, personalised and stable protocol for up to 1 year.

This line of research involves three main areas: ocular surface diseases, ophthalmological surgery and ocular fundus pathologies.

The range of pathologies that can affect the ocular surface is very varied and has different levels of severity, from mild to very serious. Among them, we find: dry eye syndrome (DES), persistent epithelial defects (PEDs), disorders of the ocular surface and scarring conjunctivitis. We are carrying out different studies on all of them. We are also investigating the use of fibrin membrane as a three-dimensional mesh for treating surgical wounds and adjuvant treatment following glaucoma surgery, persistent corneal ulcer, perforation of the cornea, surface keratoplasty and pterygium excision. Finally, it's worth highlighting that, nowadays, several ocular fundus pathologies are orphan when it comes to treatment and we are carrying out research to offer autologous alternatives taken from the patient's blood.